NFAT transcription factors are critical survival factors that inhibit cardiomyocyte apoptosis during phenylephrine stimulation in vitro - PubMed (original) (raw)
NFAT transcription factors are critical survival factors that inhibit cardiomyocyte apoptosis during phenylephrine stimulation in vitro
William T Pu et al. Circ Res. 2003.
Abstract
Biomechanical stress on the heart results in activation of numerous signaling cascades, leading to cardiomyocyte hypertrophy, apoptosis, and ultimately, heart failure. The Ca2+-dependent phosphatase calcineurin is an essential mediator of cardiac hypertrophy, and in most but not all studies, calcineurin inhibition attenuated cardiac hypertrophy in vivo. However, calcineurin inhibition has been reported to have adverse effects on cardiac remodeling and cardiomyocyte apoptosis. Calcineurin regulates the activity of a number of downstream targets, including the transcription factors NFAT, MEF2, and NF-kappaB, and the apoptotic factor Bad. To evaluate the contribution of NFAT activation by calcineurin to cardiomyocyte responses to hypertrophic stimulation, we used adenovirus to express VIVIT, a selective peptide inhibitor of calcineurin-mediated NFAT activation. We found that selective NFAT inhibition during phenylephrine stimulation inhibited hypertrophy but resulted in increased cardiomyocyte apoptosis. In contrast, nonselective inhibition of calcineurin by cyclosporin A did not cause cardiomyocyte apoptosis after phenylephrine stimulation. Cyclosporin A suppressed the effect of VIVIT on cardiomyocyte apoptosis. These results demonstrate that during phenylephrine stimulation calcineurin activates both pro- and antiapoptotic pathways in cardiomyocytes, and that NFAT activity is a critical component of the antiapoptotic pathway that regulates whether the outcome of calcineurin activation is cardiomyocyte apoptosis or survival.
Similar articles
- Regulation of nerve growth factor in the heart: the role of the calcineurin-NFAT pathway.
Rana OR, Saygili E, Meyer C, Gemein C, Krüttgen A, Andrzejewski MG, Ludwig A, Schotten U, Schwinger RH, Weber C, Weis J, Mischke K, Rassaf T, Kelm M, Schauerte P. Rana OR, et al. J Mol Cell Cardiol. 2009 Apr;46(4):568-78. doi: 10.1016/j.yjmcc.2008.12.006. Epub 2008 Dec 25. J Mol Cell Cardiol. 2009. PMID: 19150448 - Direct and indirect interactions between calcineurin-NFAT and MEK1-extracellular signal-regulated kinase 1/2 signaling pathways regulate cardiac gene expression and cellular growth.
Sanna B, Bueno OF, Dai YS, Wilkins BJ, Molkentin JD. Sanna B, et al. Mol Cell Biol. 2005 Feb;25(3):865-78. doi: 10.1128/MCB.25.3.865-878.2005. Mol Cell Biol. 2005. PMID: 15657416 Free PMC article. - Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes.
Fiedler B, Lohmann SM, Smolenski A, Linnemuller S, Pieske B, Schroder F, Molkentin JD, Drexler H, Wollert KC. Fiedler B, et al. Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11363-8. doi: 10.1073/pnas.162100799. Epub 2002 Aug 12. Proc Natl Acad Sci U S A. 2002. PMID: 12177418 Free PMC article. - Interference of antihypertrophic molecules and signaling pathways with the Ca2+-calcineurin-NFAT cascade in cardiac myocytes.
Fiedler B, Wollert KC. Fiedler B, et al. Cardiovasc Res. 2004 Aug 15;63(3):450-7. doi: 10.1016/j.cardiores.2004.04.002. Cardiovasc Res. 2004. PMID: 15276470 Review. - Calcineurin-NFAT signaling regulates the cardiac hypertrophic response in coordination with the MAPKs.
Molkentin JD. Molkentin JD. Cardiovasc Res. 2004 Aug 15;63(3):467-75. doi: 10.1016/j.cardiores.2004.01.021. Cardiovasc Res. 2004. PMID: 15276472 Review.
Cited by
- Interaction between NFκB and NFAT coordinates cardiac hypertrophy and pathological remodeling.
Liu Q, Chen Y, Auger-Messier M, Molkentin JD. Liu Q, et al. Circ Res. 2012 Apr 13;110(8):1077-86. doi: 10.1161/CIRCRESAHA.111.260729. Epub 2012 Mar 8. Circ Res. 2012. PMID: 22403241 Free PMC article. - GATA4 is a survival factor in adult cardiac myocytes but is not required for alpha1A-adrenergic receptor survival signaling.
Huang Y, Wright CD, Kobayashi S, Healy CL, Elgethun M, Cypher A, Liang Q, O'Connell TD. Huang Y, et al. Am J Physiol Heart Circ Physiol. 2008 Aug;295(2):H699-707. doi: 10.1152/ajpheart.01204.2007. Epub 2008 Jun 13. Am J Physiol Heart Circ Physiol. 2008. PMID: 18552157 Free PMC article. - Therapeutic Inhibition of LincRNA-p21 Protects Against Cardiac Hypertrophy.
Wang Y, Zhang M, Wang R, Lin J, Ma Q, Guo H, Huang H, Liang Z, Cao Y, Zhang X, Lu YW, Liu J, Xiao F, Yan H, Dimitrova N, Huang ZP, Mably JD, Pu WT, Wang DZ. Wang Y, et al. Circ Res. 2024 Jul 19;135(3):434-449. doi: 10.1161/CIRCRESAHA.123.323356. Epub 2024 Jun 12. Circ Res. 2024. PMID: 38864216 - Nuclear factor of activated T cells balances angiogenesis activation and inhibition.
Zaichuk TA, Shroff EH, Emmanuel R, Filleur S, Nelius T, Volpert OV. Zaichuk TA, et al. J Exp Med. 2004 Jun 7;199(11):1513-22. doi: 10.1084/jem.20040474. J Exp Med. 2004. PMID: 15184502 Free PMC article. - Signaling Pathways in Cardiac Myocyte Apoptosis.
Xia P, Liu Y, Cheng Z. Xia P, et al. Biomed Res Int. 2016;2016:9583268. doi: 10.1155/2016/9583268. Epub 2016 Dec 22. Biomed Res Int. 2016. PMID: 28101515 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous